

Resource Summary Report

Generated by [RRID](#) on Aug 9, 2026

MEK1/2 (47E6) Rabbit mAb

RRID:AB_331778

Type: Antibody

Proper Citation

Cell Signaling Technology Cat# 9126, RRID:AB_331778

Antibody Information

URL: http://antibodyregistry.org/AB_331778

Proper Citation: Cell Signaling Technology Cat# 9126, RRID:AB_331778

Target Antigen: MEK1/2 (47E6) Rabbit mAb

Host Organism: rabbit

Clonality: monoclonal

Comments: Applications: W

Antibody Name: MEK1/2 (47E6) Rabbit mAb

Description: This monoclonal targets MEK1/2 (47E6) Rabbit mAb

Target Organism: rat, h, m, mouse, r, human, mk

Antibody ID: AB_331778

Vendor: Cell Signaling Technology

Catalog Number: 9126

Alternative Catalog Numbers: 9126S

Record Creation Time: 20250820T030441+0000

Record Last Update: 20250820T151707+0000

Ratings and Alerts

No rating or validation information has been found for MEK1/2 (47E6) Rabbit mAb.

No alerts have been found for MEK1/2 (47E6) Rabbit mAb.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 14 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Carta L, et al. (2026) Identification of Small-Molecule Inhibitors that Block the GTP-Binding Pocket of K-Ras and Other Members of the Ras Superfamily of Small GTPases. *Molecular cancer therapeutics*, 25(1), 84.

Chatterjee D, et al. (2025) KSR1 Mediates Small Cell Lung Carcinoma Tumor Initiation and Cisplatin Resistance. *Molecular cancer research : MCR*, 23(6), 553.

Almazan J, et al. (2025) Combined inhibition of focal adhesion kinase and RAF/MEK elicits synergistic inhibition of melanoma growth and reduces metastases. *Cell reports. Medicine*, 6(2), 101943.

Lubrano S, et al. (2025) FAK inhibition combined with the RAF-MEK clamp avutometinib overcomes resistance to targeted and immune therapies in BRAF V600E melanoma. *Cancer cell*, 43(3), 428.

Roper N, et al. (2024) Functional Heterogeneity in MET Pathway Activation in PDX Models of Osimertinib-resistant EGFR-driven Lung Cancer. *Cancer research communications*, 4(2), 337.

Dong Y, et al. (2024) TSPAN4 influences glioblastoma progression through regulating EGFR stability. *iScience*, 27(8), 110417.

Fan F, et al. (2023) Combining MEK and SRC inhibitors for treatment of colorectal cancer demonstrate increased efficacy in vitro but not in vivo. *PloS one*, 18(3), e0281063.

Arang N, et al. (2023) High-throughput chemogenetic drug screening reveals PKC-RhoA/PKN as a targetable signaling vulnerability in GNAQ-driven uveal melanoma. *Cell reports. Medicine*, 4(11), 101244.

Ouyang H, et al. (2023) p120 RasGAP and ZO-2 are essential for Hippo signaling and tumor-suppressor function mediated by p190A RhoGAP. *Cell reports*, 42(12), 113486.

Tomita H, et al. (2020) The Protein Tyrosine Phosphatase Receptor Delta Regulates Developmental Neurogenesis. *Cell reports*, 30(1), 215.

Zadora PK, et al. (2019) Integrated Phosphoproteome and Transcriptome Analysis Reveals Chlamydia-Induced Epithelial-to-Mesenchymal Transition in Host Cells. *Cell reports*, 26(5), 1286.

Li H, et al. (2019) YAP/TAZ Activation Drives Uveal Melanoma Initiation and Progression. *Cell reports*, 29(10), 3200.

Rao S, et al. (2019) Leveraging Compound Promiscuity to Identify Targetable Cysteines within the Kinome. *Cell chemical biology*, 26(6), 818.

Bhargava A, et al. (2016) Registered report: RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. *eLife*, 5.